Kratom living monograph
Acute and longer-term risks, withdrawal symptoms, liver warning signs, and emergencies.
Risks
Risks range from common gastrointestinal and circulatory symptoms to dependence, withdrawal, and rare severe presentations. Product uncertainty and co-use make individual prediction difficult.
Vomiting is commonly reported. With profound sedation, vomit can be aspirated; a person with impaired consciousness must not be left alone.
Bundesinstitut für Risikobewertung (BfR), 2025WHO Expert Committee on Drug Dependence, 2021Kratom is not equivalent to classic heroin or fentanyl, yet opioid-type emergency signs can occur—especially with 7-OH products, high concentrations, or additional depressants.
WHO Expert Committee on Drug Dependence, 2021Journal of Medical Toxicology, 2019Journal of AOAC International, 2026Seizures, tachycardia, blood-pressure changes, and rhythm abnormalities have been reported. Causality and frequency are uncertain because of co-use and case-report bias.
Bundesinstitut für Risikobewertung (BfR), 2025WHO Expert Committee on Drug Dependence, 2021Regular use can accompany constipation, sleep disruption, fluctuating drive, and emotional blunting. Cause, context, and withdrawal effects can overlap.
Drug and Alcohol Dependence, 2014WHO Expert Committee on Drug Dependence, 2021Rare but clinically significant liver injury is documented, often with jaundice and a cholestatic pattern. Individual prediction is currently not possible.
Drug and Alcohol Dependence, 2021Journal of Addiction Medicine, 2026Changing alkaloid concentrations, undeclared enrichment, and contaminants make stable exposure difficult. This is especially relevant to online extracts and mixed products.
Phytochemistry, 2026Journal of AOAC International, 2026Bundesinstitut für Risikobewertung (BfR), 2025Regular use can lead to reduced effect, more frequent redosing, escalation, and use to relieve withdrawal. This is not limited to isolated 7-OH.
Drug and Alcohol Dependence, 2014Journal of Psychoactive Drugs, 2019WHO Expert Committee on Drug Dependence, 2021Withdrawal can include opioid-like physical symptoms and psychological symptoms. Intensity and duration vary with frequency, exposure, product, duration of use, and comorbidity; it is not established as “always mild.”
Journal of Psychoactive Drugs, 2019Drug and Alcohol Dependence, 2014WHO Expert Committee on Drug Dependence, 2021Seek help early with daily use, marked loss of control, severe withdrawal, pregnancy, major physical or mental illness, co-use, or suicidal thoughts. Abruptly stopping alone is not the safest option in every situation.
Daily use is not a moral failure. It is a practical signal to review tolerance, withdrawal, product strength, and co-use in a structured way.
Synapedia offers orientation but does not replace medical diagnosis or treatment.
Call 112 immediately, check breathing, do not leave the person alone, and follow dispatcher instructions. If breathing, use the recovery position; if not breathing normally, start resuscitation as directed.
For an opioid-type emergency, naloxone may be used if available and the responder knows how. Case reports describe improvement after naloxone, but response in kratom toxicity is not guaranteed. Naloxone never replaces calling 112 or ventilation/resuscitation and cannot reverse every co-ingestant hazard.
National Capital Poison Center, 2025Journal of Medical Toxicology, 2019Cureus, 2023Trust
Each source is tied to a claim domain. “Reviewed” means editorial source review—not individual medical clearance.
Bundesinstitut für Risikobewertung (BfR) · 2025
Contributes: German risk communication on products, adverse effects, and classification.
Limit: Regulatory assessment; emphasises limited evidence and is not a product-specific legal ruling.
WHO Expert Committee on Drug Dependence · 2021
Contributes: Broad international review of pharmacology, toxicity, dependence, and case reports.
Limit: Many severe cases are confounded by co-use and heterogeneous products.
Contributes: Research-based overview of effects, products, dependence, and uncertainties.
Limit: Secondary government overview, not an individual primary study.
Contributes: Government overview of benefit claims, adverse effects, and research limits.
Limit: Secondary source; not product-specific.
ACS Central Science · 2019
Contributes: Preclinical data on 7-OH formation, potency, and opioid activity.
Limit: Animal, cellular, and ex-vivo evidence; not a direct clinical dosing basis.
Drug and Alcohol Dependence · 2014
Contributes: Observational data from 293 regular users on dependence and withdrawal.
Limit: Regional, non-randomised self-report sample in a traditional-use context.
Contributes: Systematic review and case series on clinical withdrawal presentations.
Limit: Small heterogeneous case literature with publication bias; no standard withdrawal trajectory.
Drug and Alcohol Dependence · 2021
Contributes: Well-characterised cases of clinically significant kratom-associated liver injury.
Limit: Case series without incidence estimate; product composition not always fully known.
Contributes: Current systematic synthesis of published liver-injury cases.
Limit: Case-report literature cannot quantify frequency or individual risk.
Phytochemistry · 2026
Contributes: Current analytical evidence on variability across commercial products.
Limit: Product sample does not represent the entire rapidly changing market.
Journal of AOAC International · 2026
Contributes: Analytical study identifies highly enriched 7-OH products with non-leaf-like profiles.
Limit: Market sample; chemical analysis does not directly quantify clinical event rates.
Contributes: Toxicology emergency guidance, including naloxone when a person is not breathing.
Limit: US emergency context; does not replace German emergency services or clinical evidence.
Contributes: Case report of clinical improvement after naloxone.
Limit: Single case; does not establish typical effectiveness or product safety.
